Prostaglandins, their inhibitors and cancer

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 54, Issue 2, 1996, Pages 83-94

  Lupulescu, Aurel ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

AUTORADIOGRAPHY; CARCINOGENESIS; CELL SURFACE; CYTOCHEMISTRY; HUMAN; HYPOPHYSECTOMY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; ULTRASTRUCTURE;

EID: 0030000645     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90064-2     Document Type: Review

References (109)

1. Sykes J. A., Maddox A. S. Prostaglandin production by experimental tumors and effects of anti-inflammatory compounds. Nature New Biol 1972; 237: 59-61.
2. Jaffe B. M. Prostaglandins and cancer: An update. Prostaglandins 1974; 6: 453-461.
3. Easty G. C., Easty D. M. Prostaglandins and cancer. Cancer Treat Rev 1976; 3: 217-225.
4. Bennett A. Prostaglandins and cancer. In: Karim S. M., ed. Advances in Prostaglandin Research. Baltimore: University Park Press, 1979: 149.
5. Karmali R. A. Prostaglandins and cancer. Review. Prostaglandins Med 1980, 5: 11-28.
6. Levine L. Arachidonic acid transformation and tumor production. Adv Cancer Res 1981; 35: 49-79.
7. Honn K. V., Bockman R. S., Marnett L. J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 1981; 21: 833-859.
8. Smith B. J, Wills M. R., Savory J. Prostaglandins and Cancer. Ann Clin Lab Sci 1983; 13: 359-365.
9. Powles T. J. Prostaglandins and cancer. Clinical approaches In: Garaci E., Paoletti R., Santoro M. G., eds. Prostaglandins in Cancer Research. Berlin: Springer Verlag, 1987: 184.
10. Bennett A., Stamford I. F., Cooper D. Human cancer prostaglandins and patient survival. Adv Prostaglandin Thromboxane Leukot Res 1991; 21B: 875-878.
11. Lupulescu A. Effect of prostaglandins on protein, RNA, DNA, and collagen synthesis in experimental wounds. Prostaglandins 1975; 10: 573-579.
12. Lupulescu A. Cytologic and metabolic effects of prostaglandins on rat skin. J Invest Dermatol 1977; 68: 138-145.
13. Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature 1978; 272: 634-636.
14. Lupulescu A. Enhancement of carcinogenesis by prostaglandins in male albino Swiss mice. J Natl Cancer Inst 1978; 61: 97-106.
15. Lupulescu A. Hormonal regulation of epidermal tumor development. J Invest Dermatol 1981; 77: 186-195.
16. Williams E. D., Karim S. M., Sandler M. Prostaglandin secretion by medullary carcinoma of the thyroid. Lancet 1968; 1: 22-23.
17. Lupulescu A. Tumorigenic potential of endoperoxide analogs. Experientia 1984; 40: 209-211.
18. Karmali R. A. Eicosanoids and cancer. Prog Clin Mol Res 1986; 222: 687-697
19. Bennett A. Prostaglandins, tumor invasiveness and treatment with inhibitors of prostaglandin synthesis. Prog Lipid Res 1981; 20: 677-679.
20. Levine L, Hinkle P. M., Voelkel E. F., Tashjian A. H. Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochem Biophys Res Commun 1972; 47: 888-896.
21. Lynch N. R., Castes M., Astoin M., Salomon J. C. Mechanism of inhibition of tumor growth by aspirin and indomethacin. Br J Cancer 1978; 38: 503-512.
22. Tashjian A. H., Voelkel E. F., McDonough J., Levine L. Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells. Nature 1975; 258: 739-741.
23. Voelkel E. F., Tashjian A. H., Franklin R., Wasserman A. H., Levine L. Hypercalcemia and tumor-prostaglandins: the Vx2 carcinoma model in the rabbit. Metabolism 1975; 24: 973-986.
24. Ziboh V. A., Lord J. T., Blick G., Kursunoglu I., Poitier J., Yunis A. A. Alteration of prostaglandin biosynthesis in rat chloroleukemic tumor. Cancer Res 1977; 37: 3974-3980.
25. Levine L. Chemical carcinogens stimulate canine kidney (MDCK) cells to produce prostaglandins. Nature 1977; 268: 447-448.
26. Tan W. C., Privett O. S., Goldyne M. E. Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Cancer Res 1974; 34: 3229-3231.
27. Sandier M., Karim S. M., Williams E. D. Prostaglandins in aminepeptide secreting tumors. Lancet 1968; 2: 1053-1055.
28. Bhana D., Hillier K., Karim S. M. Vasoactive substances in Kaposi's sarcoma. Cancer 1971; 27: 223-237.
29. Bennett A., McDonald A. M., Simpson J. S., Stamford I. F. Breast cancer, prostaglandins, and bone metastases. Lancet 1975; 1: 1218-1220.
30. Powles T. J., Dowsett M., Easty D. M., Easty G. C., Neville A. M. Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet 1976; 1: 608-610.
31. Bennett A., Charlier E. M., McDonald A. M., Simpson J. S., Stamford I. F., Zebro T. Prostaglandins and breast cancer. Lancet 1977; 2: 624-626.
32. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980; 64: 1061-1070.
33. Karmali R. A., Welt S., Thaler H. T., Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 1983; 48: 689-696.
34. Watson D.M., Kelly R. W., Miller W. R. Prostaglandins and prognosis in human breast cancer. Br J Cancer 1987; 56: 367-370.
35. Laekeman G. M., Vergote I. B., Keersmaekers G. M., et al. Prostacyclin and thromboxane in benign and malignant breast tumors. Br J Cancer 1986; 54: 431-437.
36. Bennett A., Carroll M. A., Stamford I. F., Whimster W. F., Williams F. Prostaglandins and human lung carcinomas. Br J Cancer 1982; 46: 888-893.
37. Cummings K. B., Robertson P. R. Prostaglandin: increased production by renal cell carcinoma. J Urol 1977; 118: 720-723.
38. Karmali R. A., Wustrow T., Thaler H. T., Strong E. W. Prostaglandins in carcinomas of the head and neck. Cancer Lett 1984; 22: 333-336.
39. Suzuki M., Ohwada M., Tamada T. Plasma prostaglandin levels in patients with gynecologic malignancies and its fluctuations during chemotherapeutically-induced gastrointestinal toxicity. Jpn J Clin Oncol 1987; 17: 215-220.
40. Clark G. W., Smyrk T. C., Mirvish S. S., et al. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: An experimental rat model. Ann Surg Oncol 1994; 1: 252-261.
41. 2α. in the neoplastic cells as revealed by autoradiographic studies. Experientia 1980; 36: 246-247
42. 2α internalization in bovine luteal slices. Mol Cell Endocrinol 1984; 38: 117-129.
43. Lupulescu A. Prostaglandins and DNA synthesis in cancer cells. J Cell Biol 1982; 95: 180.
44. 2α) is inhibited by hypophysectomy. J Cell Biol 1985; 101: 483.
45. Shimizu N., Nakamura T. Prostaglandins as hormones. Dig Dis Sci 1985; 30: 109 S-113 S.
46. Jimenez De Asua L., Richmond K. V., Otto A. M. Two growth factors and two hormones regulate initiation of DNA synthesis in cultured mouse cells through different pathways of events. Proc Natl Acad Sci USA 1981; 78: 1004-1008.
47. 2α, and fibroblastic growth factor. J Cell Physiol 1983; 115: 15-22.
48. MacManus J. P., Whitfield J. F. Cyclic AMP, prostaglandins, and the control of cell proliferation. Prostaglandins 1974; 6: 475-487
49. Hughes-Fulford M., Wu J., Kato T., Fukushima M. Inhibition of DNA synthesis and cell cycle by prostaglandins independent of cyclic AMP. Adv Prostaglandin Thromboxane Leukot Res 1985; 15: 401-404.
50. 2α, and rates of cell proliferation. Pharmacol Res Commun 1979; 11: 69-75.
51. Mitchell M. D., Trautman M. S. Molecular mechanisms regulating prostaglandin action. Mol Cell Endocrinol 1993; 93: C7-C10.
52. Baumann J., Bruchhausen F., Wurm G. Flavonoids and related compounds as inhibitors of arachidonic acid peroxidation. Prostaglandins 1980; 20: 627-639.
53. 2 but also at the level of cyclo-oxygenase/PGE isomerase. Br J Pharmacol 1989; 98: 1287-1295.
54. Plescia O., Smith A., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 1975; 72: 1848-1851.
55. Perrin L. Les prostaglandins et la réponse immunitaire. Rev Fr Allergol 1974; 14: 213-217
56. Goodwin J. S. Prostaglandin E and cancer growth: potential for immunotherapy with prostaglandin synthetase inhibitors. In: Hersh E. M., Chirigos M. A., Mastrangelo M. J., eds. Augmenting Agents in Cancer Therapy. New York: Raven Press, 1981: 393.
57. Strausser H. R., Humes J. L. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in BALE/ c mice. Int J Cancer 1975; 15: 724-730.
58. Lynch N. R., Salomon J-C. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 1979; 62: 117-121.
59. Lupulescu A. Effects of prostaglandins on tumor transplantation. Oncology 1980; 37: 418-423.
60. Plescia O., Racis S. Prostaglandins as physiological immunoregulators. Prog Allergy 1988; 44: 153-171.
61. Feuerstein G., Hallenbeck J. M. Leukotrienes in health and disease. FASEB J 1987; 1: 186-192.
62. Parker C. V. Leukotrienes and prostaglandins in the immune system. Adv Prostaglandin Thromboxane Leukot Res 1986; 16: 113-130.
63. 4. Endocrinology 1988; 123: 991-1000.
64. 4 in head and neck cancer. Br J Cancer 1989; 59: 833.
65. Lupulescu A. Hormones and Vitamins in Cancer Treatment. Boca Raton, Boston: CRC Press, 1990: 119.
66. Hedge G. A., Hanson S. D. The effects of prostaglandins on ACTH secretion. Endocrinology 1972; 91: 925-933.
67. 1 on rat anterior pituitary cyclic AMP and luteinizing hormone release. Prostaglandins 1974; 5: 165-171.
68. Orczyk G. P., Behrman H. R. Ovulation blockade by aspirin or indomethacin - in vivo evidence for a role of prostaglandin in gonadotrophin secretion. Prostaglandins 1972; 1: 3-9.
69. Brown M. R., Hedge G. A. In vivo effects of prostaglandins on TRH-induced TSH secretion. Endocrinology 1974; 95: 1392-1397.
70. Lupulescu A. Goiter formation following prostaglandin administration in rats. Am J Pathol 1976; 85: 21-36.
71. Shimonovitz S., Yagel S., Anteby E. et al. Interleukin-I stimulates prostaglandin E production by human trophoblast cells from first and third trimesters. J Clin Endocrinol Metab 1995; 80: 1641-1646.
72. El Attar T. M., Lin H. S. Effect of vitamin C and Vitamin E on prostaglandin synthesis by fibroblasts and squamous carcinoma cells. Prostaglandins Leukot Essent Fatty Acids 1992; 47: 253-257.
73. 16 murine melanoma cells. Prostaglandins Leukot Essent Fatty Acids 1992; 47: 307-312.
74. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-235.
75. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol 1971; 231: 235-237
76. Ferreira S. H., Moncada S., Vane J. R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol 1971; 231: 237-239.
77. Tashjian A. H., Voelkel E. F., Goldhaber P., Levine L Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producing fibrosarcoma. Prostaglandins 1973; 3: 515-524.
78. Pollard M., Luckert P. H. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64: 1323-1327
79. Narisawa T., Sato M., Tani M., Kudo T., Takahashi T., Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981; 41: 1954-1957.
80. Fischer S. M., Mills, G. D., Slaga T. J. Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism. Carcinogenesis 1982; 3: 1243-1245.
81. Karmali R. A., Thaler H. T., Cohen L. A. Prostaglandin concentrations and prostaglandin synthetase activity in N-nitroso-methylurea-induced rat mammary adenocarcinoma. Eur J Cancer Clin Oncol 1983; 19: 817-823.
82. Sakata T., Hasegawa R., Johansson S. L., Zenser T. V., Cohen S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res 1986; 46: 3903-3906.
83. Roth G. J. The effect of aspirin on prostaglandin synthetase. Prog Lipid Res 1981; 20: 461-468.
84. Humes J. L., Winter C. A., Sadowski S. J., Kuehl F. A. Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal antiinflammatory agents. Proc Natl Acad Sci USA 1981; 78: 2053-2056.
85. Peterson D. A., Gerrard J. M., Rao G. H., White J. G. Salicylic acid inhibition of the irreversible effect of acetylsalicylic acid on prostaglandin synthetase may be due to competition for the enzyme cationic binding site. Prostaglandins Med 1981; 6: 161-164.
86. Reddy B. S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-5346.
87. Furuta Y., Hall E. R., Sanduja S., Barkley T., Milas L. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 1988; 48: 3002-3007
88. Moncada S., Vane J. R. Mode of action of aspirin-like drugs. Adv Intern Med 1979; 24: 1-22.
89. Metz S. A. Anti-inflammatory agents as inhibitors of prostaglandin synthesis in man. Med Clin North Am 1981; 65: 713-757.
90. Thun M. J., Namboodiri M. M., Heath C. W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596.
91. Rosenberg L., Palmer J. R., Zauber A. G., Warshauer M. E., Stolley P. D., Shapiro S. A hypothesis: nonsteroidal antiinflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358.
92. Marnett L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589.
93. Greenberg E. R., Baron J. A., Freeman D. H., Mandel J. S., Haile R. Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 1993; 85: 912-916.
94. Suh O., Mettlin C., Petrelli N. J. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-1177
95. Gann, P. H., Manson J. E., Glynn R. J., Buring J. E., Hennekens C. H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-1224.
96. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Willett W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-246.
97. Muscat J. E., Stellman S. D., Wynder E. L. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847-1854.
98. Baron J. A. Aspirin and Cancer. Prev Med 1995; 24: 121-124.
99. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-146.
100. Paganini-Hill A. Aspirin and colorectal cancer: The Leisure World cohort revisited. Prev Med 1995; 24: 113-115.
101. Waddell W. R., Ganser G. F., Cerise E. J., Loughry R. W. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-179.
102. Labayle D, Fischer D, Vielh P et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639.
103. Panje W. R. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107: 658-663.
104. Bilodeau J-F., Wang M., Chung F-L., Castonguay A. Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. Free Radic Biol Med 1995; 18: 47-54.
105. Earashi M, Noguchi M, Kinoshita K, Tanaka M. Effects of eicosanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line. Oncology 1995; 52: 150-155.
106. Rizk M., Abdel-Rahman M. S. Salicylamide reverses the aspirinantagonistic effect of salicylic acid on rat platelet cyclooxygenase. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 363-367.
107. Metz S. A., McRae J. R., Robertson R. P. Prostaglandins as mediators of paraneoplastic syndromes: Review and update. Metabolism 1981; 30: 299-315.
108. Lands W. E. Biosynthesis of prostaglandins. Annu Rev Nutr 1991; 11: 41-60.
109. Vane J. Towards a better aspirin. Nature 1994; 367: 215-216.